GlassScriptPhysician profile
Eli R Farhi
NPI 1932166709
$637.65
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $105 · 2021: $346 · 2022: $20.16.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $189.18 | 2019-2022 | |
| Abiomed | $164.14 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $65.33 | 2021 | |
| Boston Scientific Corporation | $42.90 | 2021 | |
| Medtronic Vascular, INC. | $37.68 | 2020 | |
| Medtronic, INC. | $35.11 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $34.97 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.73 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.64 | 2021 | |
| Cardiovascular Systems INC. | $13.80 | 2021 | |
| Philips North America LLC | $13.19 | 2019 | |
| Chiesi USA, INC. | $11.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eli Farhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.